The Computed Tomography Findings and Follow-up Course of Pulmonary Nocardiosis.

Ruihua Su, Yanhua Wen, Yuling Liufu, Xiaohuan Pan, Yubao Guan
Author Information
  1. Ruihua Su: From the Department of Radiology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou.
  2. Yanhua Wen: From the Department of Radiology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou.
  3. Yuling Liufu: From the Department of Radiology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou.
  4. Xiaohuan Pan: Department of Radiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  5. Yubao Guan: From the Department of Radiology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou.

Abstract

OBJECTIVE: Our study aimed to elucidate the computed tomography (CT) features and follow-up course of pulmonary nocardiosis patients to improve the understanding and diagnostic accuracy of this disease.
METHODS: The chest CT findings and clinical data of patients diagnosed with pulmonary nocardiosis by culture or histopathological examination in our hospital between 2010 and 2019 were retrospectively analyzed.
RESULTS: A total of 34 cases of pulmonary nocardiosis were included in our study. Thirteen patients were on long-term immunosuppressant therapy, among whom 6 had disseminated nocardiosis. Among the immunocompetent patients, 16 had chronic lung diseases or a history of trauma. Multiple or solitary nodules represented the most common CT feature (n = 32, 94.12%), followed by ground-glass opacities (n = 26, 76.47%), patchy consolidations (n = 25, 73.53%), cavitations (n = 18, 52.94%), and masses (n = 11, 32.35%). There were 20 cases (61.76%) with mediastinal and hilar lymphadenopathy, 18 (52.94%) with pleural thickening, 15 (44.12%) with bronchiectasis, and 13 (38.24%) with pleural effusion. Significantly higher rates of cavitations were observed among immunosuppressed patients (85% vs 29%, P = 0.005). At follow-up, 28 patients (82.35%) clinically improved with treatment, while 5 (14.71%) had disease progression, and 1 (2.94%) died.
CONCLUSIONS: Chronic structural lung diseases and long-term immunosuppressant use were found as risk factors for pulmonary nocardiosis. While the CT manifestations were highly heterogeneous, clinical suspicion should be raised upon findings of coexisting nodules, patchy consolidations, and cavitations, particularly in the presence of extrapulmonary infections such as those of the brain and subcutaneous tissues. A significant incidence of cavitations may be observed among immunosuppressed patients.

References

  1. Lerner PI. Nocardiosis. Clin Infect Dis . 1996;22:891–903.
  2. Bafghi MF, Eshraghi SS, Heidarieh P, et al. Nocardiosis in immune disorder disease. Malays J Med Sci . 2014;21:75–76.
  3. Lafont E, Marciano BE, Mahlaoui N, et al. Nocardiosis associated with primary immunodeficiencies (Nocar-DIP): an international retrospective study and literature review. J Clin Immunol . 2020;40:1144–1155.
  4. Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. Intern Med J . 2019;49:373–379.
  5. Takiguchi Y, Ishizaki S, Kobayashi T, et al. Pulmonary nocardiosis: a clinical analysis of 30 cases. Intern Med . 2017;56:1485–1490.
  6. Liu B, Zhang Y, Gong J, et al. CT findings of pulmonary nocardiosis: a report of 9 cases. J Thorac Dis . 2017;9:4785–4790.
  7. Mascarenhas NB, Lam D, Lynch GR, et al. PET imaging of cerebral and pulmonary Nocardia infection. Clin Nucl Med . 2006;31:131–133.
  8. Yoon HK, Im JG, Ahn JM, et al. Pulmonary nocardiosis: CT findings. J Comput Assist Tomogr . 1995;19:52–55.
  9. Duggal SD, Chugh TD. Nocardiosis: a neglected disease. Med Princ Pract . 2020;29:514–523.
  10. Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev . 2006;19:259–282.
  11. Blackmon KN, Ravenel JG, Gomez JM, et al. Pulmonary nocardiosis: computed tomography features at diagnosis. J Thorac Imaging . 2011;26:224–229.
  12. Anagnostou T, Arvanitis M, Kourkoumpetis TK, et al. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine (Baltimore) . 2014;93:19–32.
  13. Galacho-Harriero A, Delgado-Lopez PD, Ortega-Lafont MP, et al. Nocardia farcinica brain abscess: report of 3 cases. World Neurosurg . 2017;106:1053.e15–1053.e24.
  14. Ferrer A, Llorenc V, Codina G, et al. Nocardiosis and bronchiectasis. An uncommon association? Enferm Infecc Microbiol Clin . 2005;23:62–66.
  15. Riviere F, Billhot M, Soler C, et al. Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor? Eur Respir Rev . 2011;20:210–212.
  16. Zhong C, Huang P, Zhan Y, et al. Clinical features of pulmonary nocardiosis in patients with different underlying diseases: a case series study. Infect Drug Resist . 2022;15:1167–1174.
  17. Martinez Tomas R, Menendez Villanueva R, Reyes Calzada S, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology . 2007;12:394–400.
  18. Rosman Y, Grossman E, Keller N, et al. Nocardiosis: a 15-year experience in a tertiary medical center in Israel. Eur J Intern Med . 2013;24:552–557.
  19. Chen J, Zhou H, Xu P, et al. Clinical and radiographic characteristics of pulmonary nocardiosis: clues to earlier diagnosis. PLoS One . 2014;9:e90724.
  20. Kageyama A, Yazawa K, Ishikawa J, et al. Nocardial infections in Japan from 1992 to 2001, including the first report of infection by Nocardia transvalensis . Eur J Epidemiol . 2004;19:383–389.
  21. Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc . 2012;87:403–407.
  22. Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection . 2010;38:89–97.
  23. Buckley JA, Padhani AR, Kuhlman JE. CT features of pulmonary nocardiosis. J Comput Assist Tomogr . 1995;19:726–732.
  24. Kanne JP, Yandow DR, Mohammed TL, et al. CT findings of pulmonary nocardiosis. AJR Am J Roentgenol . 2011;197:W266–W272.
  25. Mehrian P, Esfandiari E, Karimi MA, et al. Computed tomography features of pulmonary nocardiosis in immunocompromised and immunocompetent patients. Pol J Radiol . 2015;80:13–17.
  26. Fujita T, Ikari J, Watanabe A, et al. Clinical characteristics of pulmonary nocardiosis in immunocompetent patients. J Infect Chemother . 2016;22:738–743.
  27. Hui CH, Au VW, Rowland K, et al. Pulmonary nocardiosis re-visited: experience of 35 patients at diagnosis. Respir Med . 2003;97:709–717.
  28. Derungs T, Leo F, Loddenkemper C, et al. Treatment of disseminated nocardiosis: a host–pathogen approach with adjuvant interferon gamma. Lancet Infect Dis . 2021;21:e334–e340.
  29. Martínez R, Reyes S, Menéndez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr Opin Pulm Med . 2008;14:219–227.
  30. Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Current treatment for Nocardia infections. Expert Opin Pharmacother . 2013;14:2387–2398.
  31. Brown-Elliott BA, Biehle J, Conville PS, et al. Sulfonamide resistance in isolates of Nocardia spp. from a U.S. multicenter survey. J Clin Microbiol . 2012;50:670–672.
  32. Lai CC, Liu WL, Ko WC, et al. Antimicrobial-resistant Nocardia isolates, Taiwan, 1998–2009. Clin Infect Dis . 2011;52:833–835.
  33. Uhde KB, Pathak S, Mccullum I Jr., et al. Antimicrobial-resistant Nocardia isolates, United States, 1995–2004. Clin Infect Dis . 2010;51:1445–1448.
  34. Kudru CU, Kumar A, Chawla K, et al. A ten-year retrospective analysis of nocardiosis in a tertiary care center of South-Coastal India. Infez Med . 2021;29:600–608.
  35. Wang H, Zhu Y, Cui Q, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021. Microbiol Spectr . 2022;10:e0156021.

MeSH Term

Humans
Follow-Up Studies
Retrospective Studies
Nocardia Infections
Tomography, X-Ray Computed
Lung Diseases
Immunosuppressive Agents

Chemicals

Immunosuppressive Agents

Word Cloud

Created with Highcharts 10.0.0patients=nocardiosisnCTpulmonarycavitationsamong94%studyfollow-updiseasefindingsclinicalcaseslong-termimmunosuppressantlungdiseasesnodules3212%patchyconsolidations185235%pleuralobservedimmunosuppressedOBJECTIVE:aimedelucidatecomputedtomographyfeaturescourseimproveunderstandingdiagnosticaccuracyMETHODS:chestdatadiagnosedculturehistopathologicalexaminationhospital20102019retrospectivelyanalyzedRESULTS:total34includedThirteentherapy6disseminatedAmongimmunocompetent16chronichistorytraumaMultiplesolitaryrepresentedcommonfeature94followedground-glassopacities267647%257353%masses11206176%mediastinalhilarlymphadenopathythickening1544bronchiectasis133824%effusionSignificantlyhigherrates85%vs29%P00052882clinicallyimprovedtreatment51471%progression12diedCONCLUSIONS:ChronicstructuralusefoundriskfactorsmanifestationshighlyheterogeneoussuspicionraiseduponcoexistingparticularlypresenceextrapulmonaryinfectionsbrainsubcutaneoustissuessignificantincidencemayComputedTomographyFindingsFollow-upCoursePulmonaryNocardiosis

Similar Articles

Cited By